Slovenia's Galex records 902% jump in sales
Murska Sobota, Slovenia-headquartered pharmaceutical company Galex has reported a 299,255-euro ($419,137) profit for its 2008 financial year, up 108% year-on-year.
Turnover was 4.7 million euros, including a 902% jump in revenue from generic drugs sold in foreign markets. Galex generated income of 1.5 million euros from total sales of products in the Slovene market, flat on 2007, while sales in foreign markets generated 1.0 million euros, a 767% increase.
Galex says it is extremely active in European Union markets, principally in the production of copy drugs. The firm has obtained several licences for products the company will be the first to offer in the European and worldwide markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze